Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trialBerend J. van der Wilk, Tanya M. Bisseling, Peter‐Paul L. O. Coene et al.|The Lancet Oncology|2025Cited by 95
Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancerJ. Jan B. van Lanschot, Ben M. Eyck, Berend J. van der Wilk et al.|Trials|2021Cited by 91
Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trialBerend J. van der Wilk, J.J.B. van Lanschot, Ben M. Eyck et al.|British journal of surgery|2020Cited by 20
Detection of circulating tumour <scp>DNA</scp> after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancerBen M. Eyck, Winand N.M. Dinjens, Maurice P.H.M. Jansen et al.|The Journal of Pathology|2022Cited by 20
Surveillance of Clinically Complete Responders Using Serial <sup>18</sup>F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant ChemoradiotherapyMaria J. Valkema, Roelf Valkema, Berend J. van der Wilk et al.|Journal of Nuclear Medicine|2020Cited by 15